Put companies on watchlist
Hardman & Co Research
ISIN: GB00BYV81293
WKN: A2AE98
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Hardman & Co Research · ISIN: GB00BYV81293 · EQS - Company News (2 News)
Country: Great Britain · Primary market: United Kingdom · EQS NID: 1773471
15 November 2023 08:30AM

Accelerating effectiveness of enlarged sales team


Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team

15-Nov-2023 / 07:30 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman & Co Research on Shield Therapeutics (STX):

Accelerating effectiveness of enlarged sales team

 

Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, with the aim of ramping up prescription (Rx) growth and sales traction. Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23 and has continued into 3Q’23, following expansion of the Shield-Viatris commercial team. In the event that the US goals are achieved, there would be considerable upside potential to the valuation.

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/stx-accelerating-effectiveness-of-enlarged-sales-team/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall

 

 

mh@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1773471  15-Nov-2023 

fncls.ssp?fn=show_t_gif&application_id=1773471&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Hardman & Co Research
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.